文献速递腹部介入CTMR

药物洗脱微球TACE治疗肝转移性平滑肌肉瘤

Drug-eluting bead transarterial chemoembolization treatment of liver-dominant metastatic leiomyosarcoma.
PubMed 文献 · Abdom Radiol (NY) · 2026-01-17

回顾性分析29例不可切除肝转移性平滑肌肉瘤患者接受多柔比星DEB-TACE治疗的安全性与疗效。中位总生存期自首次DEB-TACE起为16.3个月,自肝转移诊断起为35.8个月。3个月客观缓解率为79%,疾病控制率为96%,未见DEB-TACE相关死亡。

要点

  • DEB-TACE治疗肝转移性平滑肌肉瘤安全性良好,无30天死亡及治疗相关死亡。
  • 首次DEB-TACE后3个月客观缓解率79%,疾病控制率96%,按mRECIST评价。
  • 自首次DEB-TACE起中位肝内无进展生存期为7.8个月。

核心结论

  • DEB-TACE对不可切除的肝优势型平滑肌肉瘤患者安全有效,副作用轻微。
  • 自肝转移诊断起35.8个月的中位OS在该不可切除、化疗难治人群中很有前景。

研究设计与样本

  • 单中心回顾性研究,纳入2014年12月至2024年9月接受多柔比星DEB-TACE的肝转移性平滑肌肉瘤患者29例。
  • 29例患者中男性9例、女性20例,平均年龄60.1±12.7岁;23例(79.3%)双叶受累,6例(20.7%)单叶受累。

关键影像表现/征象

  • 79.3%的患者肝脏转移灶累及双叶,20.7%仅累及单叶。
  • 首次DEB-TACE后3个月按mRECIST评价23例(79%)达客观缓解。
  • 首次DEB-TACE后3个月疾病控制率为96%(28/29例)。

诊断标准与关键数值

  • 中位OS自首次DEB-TACE起为16.3个月(95%CI 2.2; 30.4)。
  • 中位OS自肝转移诊断起为35.8个月(95%CI 21.0; 50.6)。
  • 中位OS自原发诊断起为67.5个月(95%CI 49.2; 85.8)。
  • 中位肝内无进展生存期自首次DEB-TACE起为7.8个月(95%CI 4.5; 11.2)。
  • 3个月客观反应率79%(23/29例),疾病控制率96%(28/29例),按mRECIST标准评价。

临床应用与阅片要点

  • 肝转移性平滑肌肉瘤患者接受DEB-TACE后可用mRECIST标准于3个月评估病灶反应。
  • 双叶受累和肝外转移常见,但DEB-TACE仍可取得较高疾病控制率,提示肝优势型患者可考虑局部治疗。
  • 报告时应关注治疗后3个月病灶强化特征的改变以判断客观反应与疾病控制。

局限性

  • 单中心回顾性研究,样本量仅29例。
  • 多数患者治疗前接受过系统治疗,为化疗难治人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To analyze the safety and efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) treatment of unresectable metastatic hepatic leiomyosarcoma.

METHODS: Medical records and imaging of patients with metastatic leiomyosarcoma to the liver who underwent doxorubicin DEB-TACE from December 2014 to September 2024 were retrospectively reviewed to evaluate survival and clinical and biochemical toxicities.

RESULTS: The study included 29 patients (9 males, 20 females; average age 60.1 ± 12.7 years). Twenty-three patients (79.3%) had bilobar and 6 patients (20.7%) had unilobar disease. Twenty patients (69%) had extrahepatic metastases at the time of the first DEB-TACE. Twenty-five patients (86%) received systemic therapies before DEB-TACE, and 5 of these patients had hepatic metastasectomy. The median overall survival (OS) from the first DEB-TACE was 16.3 months (95% CI 2.2; 30.4), from diagnosis of liver metastasis was 35.8 months (95% CI 21.0; 50.6), and from primary diagnosis was 67.5 months (95% CI 49.2; 85.8). At 3 months post-DEB-TACE, the objective response was 79% (23 out of 29 patients), and the disease control rate was 96% (28 out of 29 patients), evaluated by mRECIST. The median liver progression-free survival from the first DEB-TACE was 7.8 months (95% CI 4.5; 11.2). There were two grade 3 clinical toxicities, four grade 3 laboratory toxicities, and 20 grade 1 or 2 laboratory toxicities. There was no 30-day mortality and no mortality related to DEB-TACE.

CONCLUSION: DEB-TACE is safe and effective treatment in patients with liver-dominant unresectable leiomyosarcoma with minimal side effects. The 35.8 months median OS from diagnosis of liver metastasis is very promising in this patient population with unresectable, chemotherapy-refractory disease.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Henning, Venkat, Kumar, et al. Drug-eluting bead transarterial chemoembolization treatment of liver-dominant metastatic leiomyosarcoma. Abdom Radiol (NY). 2026. PMID: 41545559. doi:10.1007/s00261-025-05356-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。